Ablynx, a Sanofi company, is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology.
The acquisition of Ablynx (June 2018) continues Sanofi’s commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules. Sanofi is committed to accelerating Ablynx’s Nanobody development programmes.
The acquisition of Ablynx (June 2018) continues Sanofi’s commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules. Sanofi is committed to accelerating Ablynx’s Nanobody development programmes.
Location: Belgium, East Flanders, Ghent
Total raised: $111.17M
Founded date: 2001
Investors 4
| Date | Name | Website |
| - | Sofinnova ... | sofinnovap... |
| - | Gilde Heal... | gildehealt... |
| 28.11.2020 | Abingworth... | abingworth... |
| - | GIMV | gimv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 28.02.2013 | - | $41.19M | - |
| 15.03.2010 | - | $68.36M | - |
| 19.02.2010 | Grant | $1.63M | - |
Mentions in press and media 19
| Date | Title | Description |
| 19.10.2024 | The Dawn of a New Era in Drug Discovery: Sanyou Bio's Super-Trillion Molecule Library | In the bustling heart of Shanghai, a revolution is brewing in the world of pharmaceuticals. Sanyou Bio, under the visionary leadership of Lang Guojun, has unveiled a groundbreaking innovation: the super-trillion molecule library. This monum... |
| 17.10.2024 | Exclusive Interview with Lang Guojun, founder of Sanyou Bio: The Key to Breaking the Bottleneck of New Drug Innovation--The Past and Future of the Super-Trillion Molecule Library | SHANGHAI, Oct. 17, 2024 /PRNewswire/ -- In the ninth year since the establishment of Sanyou Bio, Lang Guojun believes that the time is perfect to unveil the world's largest super-trillion molecule library. During the interview with Tongxiey... |
| 10.07.2024 | Antonin (Tony) de Fougerolles appointed as new Chair of etherna | Brings foundational experience in mRNA and LNP therapeutics given prior executive leadership roles at Moderna & Alnylam Will take an active role in expanding partnerships with biopharma Integrated partnership offering to customers remai... |
| 01.06.2024 | Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse | BOSTON, June 1, 2024 /PRNewswire/ -- Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse genome have been successfully replaced by... |
| 01.06.2024 | Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse | BOSTON, June 1, 2024 /PRNewswire/ -- Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse genome have been successfully replaced by... |
| 12.03.2020 | Precision biologics: the key to reducing antibiotic use in livestock? | Pathogens, as is clear to anyone tracking the outbreak of Covid-19 on humans or African Swine Fever on pigs, can inflict disastrously global impacts on public health, as well as wreaking havoc on vital food supply chains. To date, preventin... |
| 16.11.2018 | With radiotherapy en vogue, Belgian startup nabs nearly $42M in Series A funding | Interest in targeted radiation treatments was buoyed last month with Novartis’ $NVS $2.1 billion bet on Endocyte that put the spotlight on a decades-old class of drugs in the lucrative field of oncology. Belgian radiot... |
| 25.10.2017 | Term Sheet — Wednesday, October 25 | 5 Qs WITH A DEALMAKER Vijay Pande, a general partner at Andreessen Horowitz, leads investments at the cross-section of biology and computer science. Pande sits on the board of many startups including Apeel Sciences, Freenome, and Rigetti Co... |
| 18.10.2017 | Term Sheet — Wednesday, October 18 | 5 Qs WITH A DEALMAKER Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop In the Valley, Jordan is also known for mentoring investors with non-tech backgrounds. One examples is Golden State W... |
| 03.10.2017 | Ablynx files for $150M IPO to build on phase 3 boost | Ablynx has moved quickly to capitalize on the boost to its prominence and prospects provided by recent phase 3 data. The Belgian biotech has joined the reopened path from Europe to Wall Street in pursuit of $150 million (€128 million) to su... |
Show more